Skip to main content

Table 3 Bleeding outcomes

From: Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin

Outcome

Rivaroxaban

N = 32,078

# of events (%/year)

Warfarin

N = 83,971

# of events (%/year)

PS overlap weighted HR

(95%CI)

Hospitalization for major or CRNM bleed

1989 (2.17)

5542 (2.31)

0.94 (0.89–0.99)

Major or CRNM bleed

6416 (6.95)

16,710 (6.95)

1.00 (0.97–1.03)

Major bleed

834 (0.90)

2687 (1.11)

0.80 (0.74–0.97)

Critical organ bleed

321 (0.35)

1344 (0.54)

0.63 (0.55–0.72)

Intracranial hemorrhage

257 (0.29)

1008 (0.40)

0.72 (0.62–0.84)

Extracranial bleed

1732 (1.87)

4450 (1.86)

1.00 (0.95–1.07)

CRNM bleed

5614 (6.09)

14,443 (6.00)

1.02 (0.98–1.05)

  1. CI confidence interval, CRNM clinically relevant non-major, HR hazard ratio, ICH intracranial hemorrhage, ISTH International Society of Thrombosis and Haemostasis, PS propensity score